Physician profile
Christopher Budny
NPI 1598783995
$323.33
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $55.12 | 2019 | |
| Ge Healthcare | $37.78 | 2019 | |
| Shire North American Group INC | $29.78 | 2019 | |
| Pfizer INC. | $27.59 | 2019 | |
| Ironshore Pharmaceuticals INC. | $18.51 | 2019 | |
| Kaleo, INC. | $16.15 | 2019 | |
| Neos Therapeutics, LP | $15.70 | 2019 | |
| Astellas Pharma US INC | $15.65 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.70 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.14 | 2019 | |
| Novo Nordisk INC | $13.77 | 2019 | |
| Merck Sharp & Dohme LLC | $13.06 | 2019 | |
| Lilly USA, LLC | $12.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.70 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $10.80 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Budny listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.